Notably, a recent publication has verified that dasatinib, an orally available tyrosine kinase inhibitor (TKI), could inhibit the migration of NPC cell line CNE2 in vitro by repressing the phosphorylation of c-Src and its downstream molecules AKT, MEK, ERK in a dose-dependent manner [50], which further confirmed the therapeutic value of p-Src in NPC patients. Here, AKT1 is linked to nasopharyngeal carcinoma.